Moleculin Biotech(MBRX)

Focus: Moleculin Biotech is a public oncology-focused biotechnology company headquartered in Houston developing novel cancer treatments, primarily through liposomal annamycin and proprietary small molecules.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Moleculin Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Moleculin Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Pipeline & Clinical Trials

WP1220

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Phase 1

Clinical Trials (1)

NCT04702503Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Phase 1

Help build intelligence for Moleculin Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology pipeline with 8 active trials across Phase 1-3, offering exposure to drug development from preclinical through late-stage studies
Public company status provides equity upside potential and established capital markets access versus private biotech
Focused portfolio in high-impact oncology indications (AML, sarcoma, glioblastoma) with meaningful unmet medical needs

Watch Out For

Severe cash runway crisis: only $4M cash remaining in FY 2025 against $18M R&D spend and $26M net losses, indicating potential financing urgency or dilution
Zero active job openings and minimal hiring activity signal organizational constraint or restructuring; no revenue-generating products to fund operations
Preclinical patent portfolio (0 publications on record) and early-stage pipeline (1 Phase 3 trial) offer limited near-term commercial catalysts

Generated by Claude from Moleculin Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

WP1122

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT05195723Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers

Phase 1

Liposomal Annamycin

Sarcoma,Soft Tissue

Phase 1/2

Clinical Trials (1)

NCT04887298Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

Phase 1/2

Liposomal Annamycin

Leukemia, Myeloid, Acute

Phase 1/2

Clinical Trials (1)

NCT03388749Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2

Liposomal Annamycin

Leukemia, Myeloid, Acute

Phase 1/2

Clinical Trials (1)

NCT03315039Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2

Liposomal Annamycin

Leukemia, Myeloid, Acute

Phase 1/2

Clinical Trials (1)

NCT05319587Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2

Biospecimen Collection

Glioblastoma, IDH-Wildtype

Phase 2

Clinical Trials (1)

NCT05879250WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2

Placebo in combination with Cytarabine Injection

Acute Myeloid Leukaemia (AML)

Phase 2/3

Clinical Trials (1)

NCT06788756L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$18M9%

Net Income

-$26M

Cash